TY - JOUR T1 - Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance JF - Evidence Based Medicine JO - Evid Based Med SP - 10 LP - 11 DO - 10.1136/ebm1128 VL - 16 IS - 1 AU - Philip D Home Y1 - 2011/02/01 UR - http://ebm.bmj.com/content/16/1/10.abstract N2 - Commentary on: Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010;376:103–11.OpenUrlCrossRefPubMedWeb of Science Type 2 diabetes has high long-team health and resource impact, as a result of its vascular complications and needed therapies. Prevention of diabetes then seems to be attractive. Previous studies have identified that lifestyle interventions and some therapeutic approaches can prevent or delay the onset of diabetes in those with hyperglycaemia. Such therapies include metformin and thiazolidinediones. Metformin and rosiglitazone are efficacious in combination in people with diabetes, while tablet combination at submaximum dose may give additive effects with reduced side effects. Zinman and colleagues asked whether such combination of these agents could prevent deterioration to diabetes in a population at risk. Using conventional risk factors (obesity, high blood pressure and the like) to identify 992 people – screened … ER -